Showing results (291-300 of 369) with videos related to

Sort By:
Pageof 37
Translational Lung Cancer Research|September 12, 2022
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysisDongliang Bian, Siming Jiang, Yicheng Xiong, et al.
Seminars in Oncology Nursing|May 24, 2025
Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled TrialAndré Manuel da Silva Lopes, Stellio Giacomini, Ambily Ulahannan, et al.
Clinical Lung Cancer|August 8, 2025
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC RegimenAndrea Riccardo Filippi, Eliana Rulli, Diego Signorelli, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2022
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trialsGiuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, et al.
Lung Cancer (Amsterdam, Netherlands)|February 5, 2008
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?Diego Dongiovanni, Lorenzo Daniele, Carla Barone, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
JCO Global Oncology|July 19, 2022
Cancer Medicines: What Is Essential and Affordable in India?Manju Sengar, Adam Fundytus, Wilma Hopman, et al.
Trials|August 31, 2018
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trialDuneesha de Fonseka, Anna Morley, Louise Stadon, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Translational Lung Cancer Research|July 14, 2022
Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trialYanjun Xu, Zhiyu Huang, Jian Fang, et al.
Pageof 37